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has acceptable short-term survival, it is important to report longer
outcome durations and delayed complications. In this report, ret-
rospective analyses after transplantation from 2 centers from 1985
to 2003 were evaluated. Sixty-nine patients were evaluated, median
age 33 years (16–75), 43 men and 26 women, 55 had nodular
sclerosing HD, 7-lymphocyte predominant, 6-mixed cellular HD,
and 1-unknown subtype. Conditioning regimens consisted of TBI/
Cyclophosphamide in 11 patients, CBV in 38, BEAM/BEAC in 16,
and Busulfan/Cyclophosphamide in 4. Forty-nine patients received
peripheral stem cells (PSC), 17 received bone marrow (BM), and 3
received PSC plus BM. Seven patients (10%) had early mortality
(100 days) directly attributable to the transplant procedure. Four
were cardiac-related and two due to infection. Long-term non-
disease related mortality occurred in 16% secondary to MDS/
AML, cardiac, respiratory, and infectious-related causes. Thirty-
seven patients are alive, 30 patients have died, and 2 are lost to
follow-up. The OS at 5 years was 49% and 21% at 10-years,
respectively, while DFS at 5 years was 41% and 33% at 10 years,
respectively, indicating that patients were dying of other causes late
after transplantation. No difference in OS and DFS was noted
according to disease status at transplantation (CR vs active disease),
gender, or PSC vs BM. However, signiﬁcant differences were
noted in OS (P  .05) and DFS (P  .05) according to sensitivity
to salvage therapy administered prior to transplantation. Achieve-
ment of CR after transplantation had a signiﬁcant effect on OS. At
the median follow-up of 32 months, the OS is 83%, with a pre-
dicted OS at 10 years of 68%. Failure to achieve CR after trans-
plantation was associated with reduced OS, with 38% alive at 32
months, and all died by 10 years post-transplant. In conclusion,
autologous transplantation offers a good long-term survival option
for patients with relapsed/resistant HD. However, if CR is not
attained after transplantation, alternative therapies should be pur-
sued, because long-term outcomes for this patient group is dismal.
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AMIFOSTINE DOES NOT PROTECT AGAINST LIVER TOXICITY IN PA-
TIENTS RECEIVING DOSE-ESCALATED IV BUSULFAN (IVBU) AND STAN-
DARD DOSE CYCLOPHOSPHAMIDE IN AUTO BMT
Grosso, D.1, Brunner, J.1, Dessain, S.1, Ferber, A.1, Filicko, J.1,
Mookerjee, B.1, Shaw, L.2, Tedesco, N.1, Tran, H.3, Wagner, J.1,
Flomenberg, N.1 1. Thomas Jefferson University, Philadelphia, PA; 2.
University of Pennsylvania Medical Center, Philadelphia, PA; 3. M. D.
Anderson Cancer Center, Houston, TX.
Eight adult patients undergoing autologous transplant for hema-
tological malignancies were given a conditioning regimen of 4 daily
single doses of IVBU followed 24 hours later by 2 days of cyclo-
phosphamide (CP) at 60 mg/kg/day adjusted body weight. Ami-
fostine 740 mg/m2 was given just prior to each dose of IVBU and
CP in an attempt to ameliorate toxicities and allow for IVBU
dose-escalation. Dose-escalation of IVBU was based on AUC and
was done in phase I fashion. There were 4 planned cohorts, with a
targeted average daily AUC range for cohort 1 of 4400–5280
uMol-minute per day (midpoint 4800). This represents the AUC
range commonly achieved by single daily doses of 3.2mg/kg/day.
Each successive cohort of patients was to receive a dose of IVBU
that would result in an AUC that was 20% greater than the
previous group. Patients were given a test dose of 0.4 mg/kg of
IVBU over 15 minutes between 7 and 21 days prior to condition-
ing. Pharmacokinetics (PK) performed around the test dose were
used to base the ﬁrst 2 conditioning doses of IVBU. Additional
IVBU PK data was collected around conditioning doses 1and 3. If
the targeted AUC range was not achieved based on the IVBU PK
data for dose 1, IVBU doses were adjusted for days 3 and 4.
Acetaminophen and metronidazole were held during all IVBU
administration. Fungal prophylaxis was the same during IVBU test
and conditioning doses. Patients received phenytoin for seizure
prophylaxis. Five patients were enrolled in cohort 1. Three patients
achieved the desired AUC for this cohort. The other 2 exceeded
the target with AUCs that were within cohort 2 range. Despite
this, there was no VOD and only grade 0 to 1 mucositis or diarrhea
in this group. Three patients were enrolled in cohort 2 and met the
targeted average daily AUC range of 5281–6340 uMol-minute per
day (midpoint 5800) for that range. Two of 3 patients in cohort 2
developed late onset VOD (days 25, 22) and the protocol was
closed. One of these patients died from complications of VOD. In
cohort 2, there was 1 patient with grade 2 mucositis. Grade 0 to 1
mucositis and diarrhea was observed in the other patients. Amifos-
tine appears to ameliorate mucositis and diarrhea in patients re-
ceiving standard doses of IVBU and CP in autologous BMT but
does not protect against VOD in patients receiving dose-escalated
IVBU at least when combined with CP.
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DURATION OF ULCERATIVE MUCOSITIS AND OUTCOMES OF AUTOLO-
GOUS (AU) HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
FOLLOWING HIGH-DOSE MELPHALAN (MP) CONDITIONING FOR MUL-
TIPLE MYELOMA (MM)
Oster, G.1, Vera-Llonch, M.1, Ford, C.2, Lu, J.3, Khazanov, I.2,
Sonis, S.2 1. Policy Analysis, Inc (PAI), Brookline, MA; 2. Brigham and
Women’s Hospital, Boston, MA; 3. Amgen Inc, Thousand Oaks, CA.
Background: OM is a common toxicity of conditioning regi-
mens for HSCT that has been associated with adverse clinical and
economic outcomes. Methods: A retrospective study of approxi-
mately 400 consecutive HSCT recipients was undertaken at a
single academic center. Data were collected via chart review on
days with ulcerative mucositis and selected outcomes including
days with fever, days of parenteral narcotic therapy, incidence of
Grade III or IV (Common Toxicity Criteria) infection, total inpa-
tient days (LOS), and total inpatient charges. Data are reported
here for the 115 MM patients who underwent AU HSCT after
high-dose MP conditioning. Results: Mean age of study subjects
was 54 years. Seventeen percent of patients received total body
irradiation. Bone marrow was the source of most grafts. The
relationship between duration of ulcerative mucositis and the out-
comes of interest is reported below. Conclusions: Duration of
ulcerative OM is associated with worse clinical and economic
outcomes in MM patients undergoing AU HSCT following high-
dose MP conditioning (Table1).
Table 1. Outcomes of AU HSCT Following High-Dose Conditioning
for MM, by Days with Ulcerative Mucositis
Days with Ulcerative Mucositis (Quartile)
I II III IV
Outcomes n  32 n  33 n  25 n  25 P-value*
Fever days (mean,SD) 1.0 (1.9) 1.9 (3.2) 2.5 (2.5) 3.1 (3.7) .0058
Narcotic therapy days
(mean,SD) 0.7 (1.7) 3.9 (3.5) 4.4 (3.5) 8.8 (5.2) <.0001
Infection (%) 10.0 (31.3) 10.0 (30.3) 12.0 (48.0) 9.0 (36.0) .4115
LOS (mean,SD) 18.3 (3.1) 19.8 (3.5) 19.9 (3.4) 23.1 (3.5) <.0001
Inpatient charges
(mean,SD)
( 10,000) 11.7 (3.2) 12.3 (3.8) 11.8 (2.1) 15.5 (6.0) .0016
*Test for linear trend; Cochran-Armitage for dichotomous and
GLM for continuous measures.
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AUGMENTED HIGH DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE, AND
CARMUSTINE FOLLOWED BY TRANSPLANTATION WITH PERIPHERAL
BLOOD STEM CELLS (PBSC) IN THE TREATMENT OF RELAPSED OR
REFRACTORY HODGKIN’S DISEASE
Schwartz, J.E.1, Robertson, M.J.1, Cornetta, K.G.1, Cripe, L.D.1,
Nelson, R.P.1, Yiannoutsos, C.T.1, Baute, J.A.1, Wood, L.L.1,
Abonour, R.1 Indiana University, Indianapolis, IN.
Introduction: The majority of patients with advanced stage
Hodgkin’s disease are cured with conventional dose combination
chemotherapy. However, patients with disease that fails to enter a
complete remission or that recurs after ﬁrst-line chemotherapy
have a poor prognosis. High dose chemotherapy with autologous
stem cell transplantation is a highly promising treatment. We
report the results of an augmented regimen containing cyclophos-
phamide, etoposide and carmustine followed by PBSC transplan-
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